Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
December 06, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
Dr. Saeid Babaei Appointed Independent Board Member as Mydecine Moves Closer to NASDAQ Listing in Q1 2022 DENVER, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC:...
Mydecine Reports Third Quarter 2021 Financial Results and Provides Business Update
November 16, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
--To Launch Phase 2/3 Smoking Cessation Clinical Trial with Johns Hopkins University (JHU) Signed 5-Year Research Agreement with JHU to Further Mydecine’s Research of Multiple Molecules for a Variety...
Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’ Veterans & Families Forum on November 10, 2021
November 10, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Leader in Emerging Psychedelic-Assisted Psychotherapy Industry
November 04, 2021 08:30 ET
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) announces the availability of a broadcast titled, “Breaking the Habit:...
Mydecine Files Full Patent Application Covering New Formulations that Bring Nanoemulsion Technology to Traditional Medicine Ingredients
November 03, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biotechnology and digital technology company aiming to...
Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Part of Psychedelic Medicine Research Renaissance
November 02, 2021 08:30 ET
|
Mydecine Innovations Group Inc.
NEW YORK, Nov. 02, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) today announces its placement in an editorial published by...
Mydecine to Participate in Wonderland: Miami on November 8-9, 2021
October 29, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biotechnology and digital technology company focused on the...
Mydecine Reports Successful Synthesis of Novel Tryptamine Improving the Pharmaceutical Properties of Psilocin
October 27, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
Further strengthens the Company’s drug development pipeline of tryptamines by introducing novel psilocin analogues containing enhancements in safety and efficacy tailored for medical use DENVER, Oct....
Mydecine To Supply Lead Drug Candidate, MYCO-001, for Multi-Site NIDA Grant-Funded Smoking Cessation Study Lead by Dr. Matthew Johnson
October 05, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), a biopharmaceutical company focused on the treatment of...
Mydecine Completes Spin-Out of U.S. Cannabis Assets
October 01, 2021 07:30 ET
|
Mydecine Innovations Group Inc.
DENVER, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), a biopharmaceutical company focused on the treatment of...